- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07620340
AI-Supported Therapy for Depression and Anxiety Compared With Standard CBT
Evaluating the Efficacy of an AI Delivered, Neurosymbolic, Human Supervised Digital Intervention for Depression and Anxiety Versus Standard Cognitive Behavioural Therapy in Young Persons and Adults
This study is a pivotal, randomised, controlled, non-inferiority trial evaluating "Nook," an AI-delivered, neurosymbolic, clinician-supervised digital psychological intervention for depression and anxiety, compared with standard cognitive behavioural therapy (CBT). The trial will recruit 400 participants aged 16-64 years in the UK with moderate depression and/or anxiety symptoms. Participants will be randomised to receive either Nook or therapist-delivered CBT.
The primary objective is to determine whether Nook is non-inferior to CBT in reducing depression and anxiety symptoms, measured using the PHQ-9/PHQ-A and GAD-7 scales. Secondary outcomes include quality of life, functional impairment, sleep quality, treatment engagement, participant satisfaction, safety outcomes, and exploratory health economic measures.
The intervention incorporates clinician oversight and predefined escalation pathways for suicidality and clinical deterioration. Outcomes will be analysed using longitudinal mixed-effects models under an intention-to-treat framework.
Přehled studie
Postavení
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dítě
- Dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Have symptoms of Generalized Anxiety Disorder (GAD) and/or symptoms of --•Major Depressive Disorder (MDD) as the primary reason for seeking treatment (formal diagnosis not required).(as determined by a Psychological Well-being Practitioner).
- Meet symptom-severity criteria on either validated screening measure:
- Depression: PHQ-9 (or PHQ-A for young persons) total score between 10 and 19, corresponding to moderate to moderately-severe symptoms, and/or
- Anxiety: GAD-7 total score between 8 and 21, corresponding to mild to severe symptoms.
- Aged 16-64 years
- If taking psychotropic medication for depression and/or anxiety, be on a stable regimen for at least 6 weeks prior to screening, with no initiation, discontinuation, or dose change during that period.
- Have reliable access to a compatible, internet-connected device and are able to use it for screening/eligibility, and the intervention and assessments (any potential costs to participants will be clearly noted in the PIS).
- Possess sufficient English language proficiency and cognitive capacity to engage with the digital therapeutic content and complete questionnaires.
- Provide informed consent.
- Willing to be randomised and to participate in a clinically-supervised CBT-based AI programme, including completion of scheduled outcome assessments.
Exclusion Criteria:
- Depression: PHQ-9 (or PHQ-A for young persons) total score >≥ 20
- Present with a primary or comorbid diagnosis (or history of) that is unsuitable for a digital CBT-based intervention (as judged by the Investigator), including:
- Post-traumatic stress disorder (PTSD) or complex trauma
- Psychotic disorder, bipolar disorder, and/or mania
- Complex or treatment-resistant obsessive-compulsive disorder (OCD)
- Personality disorder
- Eating disorder
- Substance or alcohol use disorder
- Exhibit high-risk clinical concerns, including:
- Current suicidal ideation with intent or plan (as indicated by PHQ-9 score and/or participant disclosure)
- Suicide attempt within the past 12 months
- Ongoing self-harming behaviours
- Requirement for urgent or crisis mental-health intervention (as indicated by •PHQ-9 score and/or participant disclosure)
- In participants aged 25 years and under, current treatment with an antidepressant medication initiated or dose-adjusted within the past 12 weeks (due to the recognised
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: CBT Comparator
Participants randomised to the comparator arm will receive standard cognitive behavioural therapy (CBT) delivered remotely by qualified CBT practitioners.
Therapy will be provided in accordance with routine evidence-based clinical practice, with participants undergoing the same assessment and safety monitoring schedule as the intervention arm.
|
A course of human delivered CBT by qualified therapists
|
|
Experimentální: Nook
Description: Participants randomised to the intervention arm will receive access to Nook, a digitally delivered psychological intervention designed to support individuals experiencing symptoms of depression and anxiety.
The intervention is delivered remotely through a secure digital platform and incorporates structured therapeutic content alongside clinician oversight and safety monitoring procedures.
|
An AI-guided course of digital CBT with human clinician oversight
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Patient Health Questionnaire - 9 items (PHQ-9)
Časové okno: Starting at Baseline, taken 3-weekly, to a 9 week end-point post-randomisation
|
A symptom measure of depression, ranging from 0 to 27. 27 being severe (high).
|
Starting at Baseline, taken 3-weekly, to a 9 week end-point post-randomisation
|
|
Patient Health Questionnaire - Adolescent (PHQ-A)
Časové okno: Starting at Baseline, taken 3-weekly, with a 9 week end-point post randomisation.
|
A symptom measure of depression for adolescents, ranging from 0 to 27. 27 being severe (high).
|
Starting at Baseline, taken 3-weekly, with a 9 week end-point post randomisation.
|
|
Generalized Anxiety Disorder assessment (GAD-7)
Časové okno: Starting at Baseline, taken 9-weekly, to a 9-week end point, post-randomisation
|
A symptom measure of anxiety, ranging from 0 to 21. 21 being severe (high).
|
Starting at Baseline, taken 9-weekly, to a 9-week end point, post-randomisation
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 369133
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Velká depresivní porucha (MDD)
-
Yonggui YuanZatím nenabírámeVelká depresivní porucha (MDD)Čína
-
Daniel LindqvistLund University; KetabonNáborVelká depresivní porucha (MDD)Švédsko
-
King's College LondonCardiff and Vale University Health Board; South London and Maudsley NHS Foundation... a další spolupracovníciNáborVelká depresivní porucha (MDD)Spojené království
-
Supernus Pharmaceuticals, Inc.NáborVelká depresivní porucha (MDD)Spojené státy
-
University of PennsylvaniaNábor
-
The Second Hospital of Anhui Medical UniversityZatím nenabíráme
-
Roger McIntyreAxsome Therapeutics, Inc.NáborVelká depresivní porucha (MDD)Kanada
-
National Science and Technology Council, TaiwanUniversity College Cork; IRCCS Centro San Giovanni di Dio FatebenefratelliNáborVelká depresivní porucha (MDD)Tchaj-wan
-
Corium Innovations, Inc.Zatím nenabírámeVelká depresivní porucha (MDD)
Klinické studie na Cognitive Behavioural Therapy
-
University of AarhusNeznámýChronická obstrukční plicní nemocDánsko
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); McMaster University; Memorial... a další spolupracovníciNábor